NCT03239145 2026-03-12Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid TumorDana-Farber Cancer InstitutePhase 1 Completed62 enrolled 17 charts
NCT01290263 2017-07-02Amgen 386 for Recurrent GlioblastomaDana-Farber Cancer InstitutePhase 1/2 Completed48 enrolled 13 charts